Alliance Pharma plc

LSE APH.L

Alliance Pharma plc Current Liabilities for the year ending December 31, 2023: USD 51.62 M

Alliance Pharma plc Current Liabilities is USD 51.62 M for the year ending December 31, 2023, a -9.17% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

Alliance Pharma plc Current Liabilities for the year ending December 31, 2022 was USD 56.83 M, a 3.50% change year over year.
Alliance Pharma plc Current Liabilities for the year ending December 31, 2021 was USD 54.91 M, a 33.20% change year over year.
Alliance Pharma plc Current Liabilities for the year ending December 31, 2020 was USD 41.22 M, a 28.52% change year over year.
Alliance Pharma plc Current Liabilities for the year ending December 31, 2019 was USD 32.07 M, a -72.55% change year over year.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

LSE: APH.L

Alliance Pharma plc

CEO	Mr. Nicholas John Sedgwick
IPO Date	Nov. 22, 2001
Location	United Kingdom
Headquarters	Avonbridge House
Employees	290
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. It holds the marketing rights of approximately 80 consumer healthcare and prescription medicine products. The company also offers medical devices, food supplements, and cosmetics. Alliance Pharma plc provides its products under the Aloclair, Anbesol, Asthon and Parsons, Atopiclair, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen brand names. The company was founded in 1996 and is headquartered in Chippenham, the United Kingdom.

Key trends

Past 5 years